July 28, 2023
Takeda Pharmaceutical’s April-June revenue rose 8.9% year on year driven by robust sales of its core products such as Entyvio (vedolizumab) in the US market, offsetting the negative impact from the cancellation of its COVID-19 vaccine contract with the Japanese...read more